Researchers found brain swelling in 35% of Alzheimer’s disease patients using aducanumab, a drug treatment newly approved by the Food and Drug Administration.
A study published Monday in the medical journal JAMA Neurology reported that 362 of 1,029 patients with Alzheimer’s disease who received the drug experienced brain inflammation in ...
from The Washington Times stories: Health https://ift.tt/3r4Qqjp